Andere Sprachen DURECT Corporation Deutsche Boerse AG

Aktien

A3DZZ2

US2666055007

DC8A

Markt geschlossen - Deutsche Boerse AG Andere Börsenplätze 21:50:00 17.07.2024			% 5 Tage	% 1. Jan.
1,28 ^EUR	+6,67 %		+7,56 %	+143,81 %

21.05.	DURECT Corporation erhält von der FDA den Status eines Therapiedurchbruchs für Larsucosterol bei Alkohol-assoziierter Hepatitis	CI
21.05.	Sektor-Update: Aktien des Gesundheitswesens steigen am Dienstagnachmittag	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	21.05.
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	21.05.
Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment	21.05.
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	21.05.
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	14.05.
Durect: Q1 Earnings Snapshot	13.05.
DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Earnings Flash (DRRX) DURECT CORPORATION Reports Q1 Revenue $1.8M, vs. Street Est of $2.7M	13.05.
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update	13.05.
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update	07.05.
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis	30.04.
Durect: Q4 Earnings Snapshot	27.03.
DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 Revenue $2.7M, vs. Street Est of $2.7M	27.03.
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27.03.
DURECT Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.03.
North American Morning Briefing : Stocks Edge -2-	27.03.
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update	20.03.
North American Morning Briefing : Stock Futures -2-	19.03.
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen DURECT Corporation Deutsche Boerse AG

Aktien

A3DZZ2

US2666055007

DC8A

Andere Sprachen

Filter